Trials / Recruiting
RecruitingNCT04755920
SGM-101 in Colorectal Brain Metastases.
A Feasibility Study of SGM-101, a Fluorochrome-labeled Anti-carcinoembryonic Antigen Monoclonal Antibody for the Intraoperative Detection of Colorectal Brain Metastases.
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Leiden University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study assesses the feasibility of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen monoclonal antibody, for intraoperative near-infrared fluorescence imaging of colorectal brain metastases by injecting SGM-101 intravenously 3 - 5 days prior to surgery.
Conditions
- Rectal Neoplasms
- Rectum Cancer
- Colorectal Neoplasms
- Brain Metastases
- Brain Neoplasms
- Brain Diseases
- Brain Cancer
- Brain Tumor
- Intestinal Neoplasms
- Gastrointestinal Neoplasms
- Gastrointestinal Cancer
- Gastrointestinal Disease
- Intestinal Disease
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGM-101 | Fluorescence-guided surgery |
Timeline
- Start date
- 2024-01-01
- Primary completion
- 2026-02-01
- Completion
- 2026-02-01
- First posted
- 2021-02-16
- Last updated
- 2024-05-09
Locations
2 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT04755920. Inclusion in this directory is not an endorsement.